Galderma Group AG (SIX: GALD) announced on October 22, 2026, that China’s National Medical Products Administration had approved Relfydess, or relabotulinumtoxinA, for the temporary improvement of moderate-to-severe glabellar lines in adults. The approval covers the company’s ready-to-use liquid botulinum toxin type A formulation and is supported by a Chinese Phase 3 clinical trial and the international READY development programme. The decision expands Relfydess into another important aesthetic medicine market, bringing its global regulatory footprint to 37 markets as of Galderma’s latest financial update.
The Chinese authorisation provides Galderma with an additional opportunity to expand its injectable aesthetics portfolio beyond established products such as Dysport. Relfydess is designed to offer a ready-to-use formulation without the reconstitution step required for some conventional botulinum toxin products, while its clinical development programme has demonstrated a rapid onset of action and sustained improvements in glabellar line appearance in selected patients.
The commercial significance extends beyond gaining permission to sell another wrinkle treatment. China’s aesthetic medicine industry includes established international neuromodulators and competing domestic products, making clinical differentiation, practitioner preference and treatment economics important factors in adoption. Galderma must now translate its clinical evidence and manufacturing capabilities into sustained demand within a competitive provider-driven market.
What did the Chinese Phase 3 trial demonstrate about Relfydess efficacy in frown lines?
The Chinese regulatory decision was supported by local Phase 3 evidence showing that Relfydess produced significantly greater improvements in moderate-to-severe glabellar lines than placebo. According to Galderma, 72.4% of participants receiving Relfydess achieved the specified composite response at Month 1, compared with 1.6% of placebo recipients. This corresponds to a 70.8-percentage-point difference between the treatment groups.
The composite endpoint required participants to achieve a glabellar line severity score of none or mild, together with an improvement of at least two grades from baseline. Importantly, the endpoint incorporated both investigator and participant assessments at maximum frown. The dual-assessment requirement provides a more demanding measure than an endpoint based solely on a clinician’s judgement.
The Chinese findings were directionally consistent with the international READY-1 study, which reported a composite response rate of 82.9% among Relfydess recipients and 0% among placebo recipients at Month 1. This agreement between local and international evidence is relevant because regulators often consider whether clinical findings apply to the population in which a medicine will be marketed. However, the difference between the reported percentages should not be interpreted as evidence that the treatment performs better in one country than another.
Clinical trial populations can differ in baseline wrinkle severity, demographic composition, assessment procedures and other characteristics. Without a valid head-to-head comparison under common conditions, differences between response rates do not establish differences in underlying treatment effectiveness. The regulatory importance of the Chinese study lies in demonstrating efficacy in the locally investigated population rather than producing the highest numerical response rate.
Galderma reported that the wider READY programme involved more than 2,300 participants across its studies. This provides a broader evidence base than a single registration trial, although individual studies addressed different research objectives. The complete clinical package, including safety, duration of effect and repeat-treatment observations, underpins the company’s international development strategy.
The efficacy endpoint also has a defined clinical meaning. A composite two-grade improvement indicates a substantial change on the rating scales used in the trial, but it does not measure every aspect of patient satisfaction or guarantee identical aesthetic results for all patients. Treatment outcomes can vary according to muscle activity, baseline anatomy, injection technique and individual response.
Can Relfydess deliver faster onset and longer-lasting results than conventional neuromodulators?
One of Relfydess’ principal differentiation claims concerns the speed at which patients may begin to notice improvement. In the READY-1 trial, 39% of participants reported an onset of effect from the first day after treatment. This finding indicates that some patients experienced an early visible response, although it also means that most participants did not report such an effect on Day 1.
Speed of onset may be commercially relevant because patients often schedule aesthetic procedures around professional, social or personal commitments. A treatment that produces visible effects within a shorter interval could offer convenience, provided the result is accompanied by acceptable tolerability. However, the reported Day 1 figure comes from a specific clinical study and should not be presented as proof that Relfydess acts faster than every competing botulinum toxin product.
Duration is another important feature. In READY-1, Kaplan-Meier analysis indicated that 75% of participants still demonstrated at least a one-grade improvement from baseline on both investigator and participant assessments at approximately 169 days. This supports the company’s description of sustained effects approaching six months in some patients.
That endpoint must be distinguished from the more demanding composite two-grade response measured at Month 1. Maintaining at least a one-grade improvement does not necessarily mean that the original maximum response persisted unchanged. Consequently, describing the result as six months of complete wrinkle correction would overstate the clinical evidence.
Longer-lasting treatments can potentially reduce the number of appointments required over a year, but actual treatment intervals depend on individual response and clinical practice. The duration of benefit also has to be weighed against the practical characteristics of an injectable neuromodulator, including the possibility of unwanted effects that cannot be immediately reversed.
For Relfydess, the available evidence supports a rapid response in a proportion of patients and persistent measurable improvement in many participants. It does not establish direct superiority over Botox, Dysport or other neuromodulators because the cited trials were primarily placebo-controlled rather than designed to make definitive comparisons with competing products.
How does Galderma’s ready-to-use liquid formulation affect clinical workflow and product differentiation?
Relfydess is developed using Galderma’s proprietary PEARL Technology and is supplied as a liquid formulation designed for use without reconstitution. Traditional lyophilised botulinum toxin preparations require healthcare professionals to add an appropriate diluent before administration. Eliminating this preparation step could simplify certain aspects of handling and support consistency in the volume delivered.
For aesthetic clinics, preparation requirements are part of a wider operational workflow involving product storage, patient consultation, injection planning, administration and documentation. A ready-to-use formulation may reduce the number of preparation steps and associated handling activities. Its practical value, however, depends on the approved instructions for use, storage requirements, shelf life and individual clinic processes.
Ready-to-use presentation should not be confused with autonomous administration or a lower need for clinical expertise. Botulinum toxin treatments require appropriate anatomical knowledge, dose selection and injection technique. A formulation that is easier to prepare does not eliminate the possibility of treatment-related complications arising from injection placement or drug effects.
The clinical units used for botulinum toxin products are also product-specific. Units of biological activity cannot automatically be substituted across different formulations or manufacturers. Healthcare professionals introducing Relfydess must therefore understand its specific dosing requirements rather than assuming direct equivalence with an existing neuromodulator.
The product is manufactured at Galderma’s Aesthetic Center of Excellence in Uppsala, Sweden. Centralised manufacturing creates opportunities for consistent quality systems and product control across markets, but international expansion also requires regulatory compliance, supply planning and reliable distribution. Commercial success in China will depend partly on translating global manufacturing capabilities into dependable local product availability.
The ready-to-use formulation provides a credible operational distinction, especially when combined with evidence of clinical efficacy. Nevertheless, clinics will evaluate it alongside purchase costs, expected treatment duration, adverse-event experience and patient demand. The convenience of preparation alone is unlikely to determine long-term market share.
What does the READY clinical programme reveal about the safety of relabotulinumtoxinA?
The published READY-1 trial provides detailed safety information from a randomised, double-blind, placebo-controlled Phase 3 study involving 297 treated adults. Treatment-emergent adverse events occurred in 19.4% of participants receiving relabotulinumtoxinA and 18.7% of placebo recipients. Investigators considered adverse events related to the active treatment or injection procedure in 3.6% of relabotulinumtoxinA recipients.
The most frequently identified related events included headache in 2.3% of treated participants, eyelid ptosis in 0.9% and injection-site bruising in 0.5%. The related events were generally mild, and the publication reported no severe treatment-related events during the study. These findings provide useful clinical context for the Chinese approval, although they do not eliminate the possibility of uncommon or longer-term risks.
Eyelid ptosis is particularly relevant to aesthetic treatment because even a temporary drooping eyelid may be consequential for patients seeking an elective cosmetic improvement. Such events can result from the local effects of botulinum toxin on adjacent muscles. The possibility reinforces the importance of appropriate technique, dose selection and patient assessment.
Botulinum toxin products can also carry risks associated with unintended toxin effects beyond the intended injection area, depending on the product and clinical circumstances. The absence of a particular complication in a trial does not establish that it cannot occur after wider commercial use. Regulatory labelling and post-marketing safety surveillance remain important components of product risk management.
The Chinese approval announcement described treatment-related adverse events across the supporting programme as occurring at relatively low frequency and being predominantly consistent with expected local effects. However, the release did not provide a complete adverse-event table from the Chinese Phase 3 trial. The most detailed publicly available numerical safety information therefore comes from the published international evidence.
For a treatment administered to otherwise healthy adults for cosmetic purposes, the benefit-risk threshold differs from that of a medicine used for a serious medical condition. Patients and clinicians may have limited tolerance for complications because treatment is generally elective. This makes predictable outcomes and appropriate counselling central to successful clinical adoption.
Why does China’s approval matter while Relfydess remains unapproved in the United States?
The Chinese decision expands Relfydess’ international regulatory footprint, but its status differs across jurisdictions. The product is authorised in 37 markets according to Galderma’s October 22 financial update, including countries in Europe and the Asia-Pacific region. The company has already introduced the product commercially in several international markets.
In the United States, the regulatory pathway remains unresolved. Galderma disclosed on July 1, 2026, that the Food and Drug Administration had issued a Complete Response Letter concerning the biologics license application for relabotulinumtoxinA. The company’s announcement identified observations from a manufacturing-site inspection and analytical method optimisation as the matters raised in the letter.
A Complete Response Letter means that the application cannot be approved in its current form. It does not automatically establish that the medicine is ineffective or that its clinical studies have failed. The distinction matters because the United States regulatory setback relates to manufacturing and analytical requirements disclosed by the company, while the Chinese approval reflects a separate jurisdiction’s assessment.
Galderma stated in its latest October financial update that it was targeting resubmission of the United States application during the first quarter of 2027, subject to further regulatory feedback. That timetable remains an expectation rather than a confirmed approval date. Any resubmission would still require FDA assessment, and the eventual decision cannot be assumed.
This geographical difference illustrates a common challenge in global pharmaceutical commercialisation. A medicine may have authorisation in numerous countries while additional regulatory issues remain in another jurisdiction. Companies must satisfy the specific evidence, manufacturing and quality requirements applicable to each market.
The approval in China therefore represents a genuine commercial milestone without resolving the United States regulatory process. For Galderma, success will require managing international launches while completing the remaining work needed to support approval in another major aesthetics market.
How does Relfydess fit into Galderma’s latest financial performance and injectable aesthetics strategy?
Galderma announced record net sales of $4.765 billion for the first nine months of 2026, representing 25.1% year-on-year growth at constant exchange rates. Injectable Aesthetics generated approximately $2.174 billion in sales, increasing 13.2% at constant currency. Within that division, neuromodulator sales reached $1.259 billion, with constant-currency growth of 16.9%.
The figures establish that injectable neuromodulators are already a substantial business for Galderma. Relfydess adds another product to an established commercial portfolio rather than requiring the company to create an entirely new market presence. Existing relationships with aesthetic practitioners, distributors and training organisations may support its introduction, although the company has not disclosed a separate China revenue forecast for Relfydess.
The company’s October trading update also raised full-year 2026 constant-currency sales growth guidance to 22.5% to 23.5%, compared with its previous expectation of 19% to 21%. Management confirmed its core EBITDA margin outlook of approximately 26% at constant currency. The stronger group outlook reflects performance across several businesses and should not be attributed specifically to the Chinese Relfydess authorisation.
The China approval adds a potential source of future growth to the neuromodulator division, particularly as the company continues introducing Relfydess across previously authorised markets. However, the timing of commercial availability, initial clinic adoption and pricing will determine the revenue contribution. Approval does not necessarily mean that broad product distribution or meaningful sales have already begun.
Galderma’s established Dysport franchise provides another strategic consideration. The company must determine how to position Relfydess alongside existing products without unnecessarily shifting customers between treatments that generate similar economics. Offering different formulations may help address varied practitioner preferences, but portfolio-level growth will depend on expanding demand or increasing competitiveness.
The company’s wider portfolio also includes injectable fillers, biostimulators, dermatological skincare products and therapeutic dermatology medicines. This diversification reduces dependence on any single aesthetic product. Nevertheless, a successful global Relfydess rollout could strengthen the profitability and competitive position of its injectable aesthetics business.
What will determine whether Relfydess succeeds in China’s competitive aesthetic medicine market?
The immediate commercial priority is translating the regulatory authorisation into product availability and adoption by qualified aesthetic practitioners. Clinics will need access to appropriate training, dosing information and reliable supply. Galderma will also need to establish how the product’s ready-to-use formulation and clinical results compare with the practical requirements of existing treatments.
Patient preferences could support demand for treatments offering rapid onset and persistent improvement. However, survey findings reported by Galderma should be interpreted as expressions of consumer interest rather than evidence of future purchasing behaviour. Actual demand will depend on treatment costs, provider recommendations, patient experience and the availability of competing options.
Post-marketing safety information will become increasingly important as use expands beyond controlled clinical trial populations. A larger treated population can reveal uncommon adverse events and provide additional evidence about the consistency of clinical outcomes. Such experience may influence practitioner confidence and the product’s positioning within the market.
Galderma’s simultaneous progress in China and unresolved regulatory work in the United States creates two distinct milestones. In China, the next commercial test involves distribution, training and sustained uptake. In the United States, the company must address the outstanding FDA requirements and support a successful regulatory decision.
The Chinese approval establishes that Relfydess has met the requirements for its specified cosmetic indication in that jurisdiction. Its longer-term commercial significance will be determined by whether clinical performance, operational convenience and patient experience generate demand beyond the initial launch period. With a substantial neuromodulator business already in place, Galderma has an established platform from which to pursue that growth, but the competitive differentiation of Relfydess must ultimately be demonstrated in clinical practice.
